Search
Cetalkonium
go.drugbank.com/drugs/DB11583ApprovedWithdrawnCetalkonium is a C16 alkyl benzalkonium chloride derivative with an amphipathic property which allows it to be used in different types of formulations. … [L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113]
Categories: Compounds used in a research, industrial, or household settingGadopentetic acid
go.drugbank.com/drugs/DB00789ApprovedInvestigational(From Martindale, The Extra Pharmacopoeia, 30th ed, p706) … A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs.
Categories: Compounds used in a research, industrial, or household settingAntipyrine
go.drugbank.com/drugs/DB01435Approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p29) … An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver.
Garadacimab
go.drugbank.com/drugs/DB15629Approved[L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan. … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.
Categories: Drugs Used in Hereditary AngioedemaExenatide
go.drugbank.com/drugs/DB01276ApprovedInvestigational[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. … Bydureon BCise, an auto-injector extended-release formulation, remains available.[L42700]
Categories: Drugs Used in DiabetesProducts: BYDUREON® PEN, BYDUREON POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION IN PRE-FILLED PEN 2MGDihydrocodeine
go.drugbank.com/drugs/DB01551ApprovedIllicitIt was marketed in 1911. … It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis
Mixtures: Poly-tussin EXProducts: PARACODIN N, PARACODIN N TROPFENDoconexent
go.drugbank.com/drugs/DB03756ApprovedInvestigationalIt is an omega-3 fatty acid and primary structural component of the human brain, cerebral cortex, skin, and retina thus plays an important role in their development and function.
Synonyms: 22:6(n-3)Mixtures: Live-well™ Toco-E Capsule, Virt-Pn DHATeclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking … Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells.
Vericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigational[L31178] Although not the first sGC stimulator to be granted FDA approval ([riociguat] was approved in 2013 for use in pulmonary hypertension),[L3955] vericiguat is unique amongst its peers in that modifications … [L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure.
Categories: Vasodilators Used in Cardiac DiseasesAlmitrine
go.drugbank.com/drugs/DB01430ApprovedAlmitrine is a respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. … It is used in the treatment of chronic obstructive pulmonary disease.
Categories: Compounds used in a research, industrial, or household setting